Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jun 26, 2021; 9(18): 4500-4505
Published online Jun 26, 2021. doi: 10.12998/wjcc.v9.i18.4500
Published online Jun 26, 2021. doi: 10.12998/wjcc.v9.i18.4500
Anti-tumor effect of statin on pancreatic adenocarcinoma: From concept to precision medicine
Chung-Tsui Huang, Department of Gastroenterology and Hepatology, Far Eastern Memorial Hospital, New Taipei 220, Taiwan
Yao-Jen Liang, Graduate Institute of Applied Science and Engineering, Department and Institute of Life Science, Fu-Jen University, New Taipei 242, Taiwan
Author contributions: Huang CT wrote the manuscript; Liang YJ contributed to teaching physician Huang CT regarding the idea, title and how to research papers for the review article.
Conflict-of-interest statement: There is no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yao-Jen Liang, PhD, Professor, Graduate Institute of Applied Science and Engineering, Department and Institute of Life Science, Fu-Jen University, No. 510 Zhongzheng Road, Xinzhuang District, New Taipei 242, Taiwan. 071558@mail.fju.edu.tw
Received: January 27, 2021
Peer-review started: January 27, 2021
First decision: February 27, 2021
Revised: March 11, 2021
Accepted: March 31, 2021
Article in press: March 31, 2021
Published online: June 26, 2021
Peer-review started: January 27, 2021
First decision: February 27, 2021
Revised: March 11, 2021
Accepted: March 31, 2021
Article in press: March 31, 2021
Published online: June 26, 2021
Core Tip
Core Tip: A statin is a cholesterol-lowering agent, which inhibits HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase and subsequently reduces the cholesterol precursor, and was first used commercially in 1987. This is a mini-review of statin use in pancreatic adenocarcinoma, focusing on the therapeutic effect. A search of relevant literature from 1992 to 2021 was conducted. The effect of microbiota on the tumor microenvironment of pancreatic adenocarcinoma is a new therapeutic approach as statins can modulate the gut microbiota.